Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

被引：0
|
作者：
Bischoff, H. G. [1 ]
Rueckert, A. [2 ]
Reinmuth, N. [3 ]
Grohe, C. [4 ]
Bohnet, S. [5 ]
zum Bueschenfelde, C. M. [6 ]
机构：
[1] Univ Heidelberg Hosp, Thoraxklin, Heidelberg, Germany
[2] Schwarzwald Baar Klinikum, Klin Innere Med Onkol Hamatol Immunol Infektiol &, Villingen Schwenningen, Germany
[3] Asklepios Fachkliniken Gauting, Onkol Klin Pneumol, Gauting, Germany
[4] Evangel Lungenklin Berlin, Klin Pneumol, Berlin, Germany
[5] UKSH Lubeck, Med Klin 3, Lubeck, Germany
[6] St Vincentius Kliniken, Karlsruhe Abt Innere Med 2, Karlsruhe, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
980
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [21] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
  • [22] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Lee, C. K.
    Laktionov, K.
    Yang, T. Y.
    Yu, Y.
    Kato, T.
    Jiang, L.
    Chewaskulyong, B.
    Geater, S. Lucien
    Maurel, J. M.
    Rojas, C.
    Havel, L.
    Shepherd, F. A.
    Tanaka, K.
    Ghiorghiu, D.
    Monterroso, E. Armenteros
    Huang, X.
    Yang, J. C. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1311 - S1312
  • [23] Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 3 - 4
  • [24] Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
    Janne, P.
    Planchard, D.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S. -W.
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdivieso, N.
    Ahmed, S.
    Maurel, J. -M.
    Andrasina, I.
    Goldman, J.
    Ghiorghiu, D.
    Kulkarni, D.
    Huang, X.
    Kobayashi, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S36 - S37
  • [25] FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
    Janne, Pasi A.
    Kobayashi, Kunihiko
    Robichaux, Jacqulyne
    Lee, Chee Khoon
    Sugawara, Shunichi
    Yang, Tsung-Ying
    Kim, Tae Min
    Yanagitani, Noriko
    Kim, Sang-We
    Markovets, Aleksandra
    Bhetariya, Preetida
    Poole, Lynne
    Ghiorghiu, Dana
    Hartmaier, Ryan
    Yang, James Chih-Hsin
    Planchard, David
    CANCER RESEARCH, 2024, 84 (07)
  • [26] COMPEL: Chemotherapy with/without Osimertinib in Patients with EGFRm advanced NSCLC and Progression on first-line Osimertinib
    Tufman, Autoren A.
    Sequist, L.
    Peled, N.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    de Wit, M.
    PNEUMOLOGIE, 2023, 77 : S8 - S8
  • [27] COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
    Sequist, L. V.
    Peled, N.
    Tufman, A.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1101 - S1101
  • [28] A Comparison of Sequential EGFR-TKI Therapy Versus First-Line Osimertinib in NSCLC: A Multi-Center, Retrospective Study
    Lee, C.
    Miao, E.
    Chung, S.
    Ahmed, I.
    Kohn, N.
    Patel, K.
    Stefanov, D.
    Seetharamu, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S589 - S589
  • [29] Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC
    Lin, C.
    Su, W.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S484 - S484
  • [30] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
12345